And continued successful execution of R&D and Commercialization strategies TORONTO, CANADA, December 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn”), a biotechnology company, researching, developing,…

Phase III trial confirmed to cost CA$3.75 million, with UK Government agencies funding 66% of this cost TORONTO, CANADA, 13 Nov, 2022 – Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF,…

Trondheim in central Norway will be the location of Awakn’s 4th clinic TORONTO, CANADA, Dec 1, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company…

Awakn’s Nordic expansion begins with new Awakn Clinics Oslo TORONTO, CANADA, Nov 23, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and…

TORONTO, CANADA, 17 Nov, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

Awakn will Partner with Nushama, One of New York’s Leading Ketamine-assisted Therapy Centers TORONTO, CANADA, Nov 9, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology…

Awakn will receive approx. CAD$775K to grow its Nordic clinics business TORONTO, CANADA, Oct 25, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a revenue-generating biotechnology company researching,…

Awakn delivered revenue growth of 34% in Q2 Awakn also announces closing of first tranche of private placement financing TORONTO, CANADA, Sept 15, 2022 – Awakn Life Sciences Corp. (NEO:…

TORONTO, CANADA, Sept, 12 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on…

Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine TORONTO, CANADA, August 25, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…

Licensing Partnership with Wellbeings® marks entry into Canadian addiction treatment and relapse prevention market TORONTO, CANADA, August 18, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating…

Awakn enters the U.S. addiction treatment and relapse prevention market TORONTO, CANADA, August 15, 2022 – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a revenue-generating biotechnology company researching, developing,…